The global pulmonary drug delivery systems market was valued at approximately USD 53.24 billion in 2023 and is projected to reach USD 72.33 billion by 2030, expanding at a compound annual growth rate (CAGR) of 4.6% from 2024 to 2030. This growth is primarily driven by the increasing prevalence of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis.

Key Market Trends & Insights

  • North America pulmonary drug delivery systems market dominated the market with largest revenue share of 32.0% in 2023.
  • The U.S. pulmonary drug delivery systems market dominated the North America market with a share of 77.7% in 2023.
  • Based on application, the chronic obstructive pulmonary disease (COPD) segment accounted for the largest market share in 2023.
  • Based on product, the inhalers segment accounted for the largest market share of 62.8% in 2023.
  • Based on end use, the home care segment is expected to register the fastest CAGR during the forecast period.

Market Size & Forecast

  • 2023 Market Size: USD 53.24 Billion
  • 2030 Projected Market USD 72.33 Billion
  • CAGR (2024-2030): 4.6%
  • North America: Largest market in 2023

The market's growth trajectory is influenced by several factors:

  • Increasing Disease Burden: The rising incidence of asthma and COPD globally is a significant contributor to the demand for pulmonary drug delivery systems.
  • Aging Population: An aging global population is more susceptible to respiratory conditions, thereby increasing the need for effective drug delivery solutions.
  • Healthcare Accessibility: Improved access to healthcare services in emerging markets is facilitating the adoption of advanced pulmonary drug delivery technologies.

Order a free sample PDF of the Pulmonary Drug Delivery Systems Market Intelligence Study, published by Grand View Research.

Key Companies & Market Share Insights

Leading companies in the pulmonary drug delivery systems market include:

  • AstraZeneca PLC: Known for its respiratory portfolio, including treatments for asthma and COPD.
  • GlaxoSmithKline PLC: Offers a range of inhaled therapies for respiratory diseases.
  • Boehringer Ingelheim GmbH: Provides innovative inhalation treatments for COPD.
  • Novartis AG: Engaged in developing novel inhalation therapies.
  • Cipla Ltd.: Supplies affordable inhalation products, particularly in emerging markets.

These companies are focusing on strategic initiatives such as mergers and acquisitions, product innovations, and expanding their geographic presence to strengthen their market position.

Key Companies List

  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Cipla Ltd.
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • 3M Health Care
  • PARI Pharma
  • Philips Respironics

Conclusion

The pulmonary drug delivery systems market is poised for significant growth, driven by the increasing prevalence of respiratory diseases, technological advancements, and strategic initiatives by key market players. As the demand for effective and efficient drug delivery solutions rises, companies in this sector are expected to continue innovating and expanding their offerings to meet the evolving needs of patients worldwide.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.